Podcast/Educational Content

Adverse event management in gastric/ gastroesophageal junction cancer treatment: the vital role of the multidisciplinary team in supporting treatment with Claudin18.2 targeted therapy with emphasis on zolbetuximab

This presentation focuses on adverse event management in gastric and gastroesophageal junction (GEJ) cancer treatment, with an emphasis on Claudin 18.2 (CLDN18.2)-targeted therapy and zolbetuximab. It highlights effective strategies for managing side effects and the vital role of the multidisciplinary team in patient care.

Additionally, an engaging fireside chat features two providers discussing real-world treatment of gastric and GEJ adenocarcinoma through two unique patient cases. They explore key stages from diagnosis and biomarker profiling to infusion-related management with agents like zolbetuximab, underscoring the importance of collaboration and shared decision-making for optimal outcomes.

 

Patient cases disclaimer: These patient case studies are being discussed for educational purposes. Individual treatment plans and results may vary. This information should not replace the clinical judgement of the healthcare provider.

 

MA-MM-15815

Meet the Faculty
Matthew Strickland, MD

Matthew Strickland, MD
Medical Oncologist
Tucker Gosnell Center for Gastrointestinal Cancers
Massachusetts General Hospital Cancer Center

Leslie Swanson, ARNP

Leslie Swanson, ARNP
Advanced Registered Nurse Practitioner, Fred Hutch Cancer Center
Teaching Associate
University of Washington School of Medicine